Cymabay Therapeutics Inc
NASDAQ: CBAY
$32.48
+$0.00 (+0.0%)
Closing Price on April 1, 2024
CBAY Stock Chart and Intraday Price
CBAY Stock Data
| Asset Type | Stock |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | 3876 BAY CENTER PLACE, HAYWARD, CA, US |
| Fiscal Year End | December |
| Latest Quarter | 12/31/2023 |
| Market Cap | 3,699.52M USD |
| Shares Outstanding | 114,785,000 |
CBAY Articles
Tuesday's top analyst upgrades and downgrades included Amgen, CF Industries, Coterra Energy, CymaBay Therapeutics, Eaton, Marriott, Monster Beverage, Mosaic, Nutrien, Public Service Enterprise, Urban...
Published:
Friday's top analyst upgrades and downgrades included Advanced Micro Devices, Asana, Etsy, Exact Sciences, Guardant Health, Hilton Worldwide, Meta Platforms, MongoDB, Salesforce, ServiceNow, Sysco...
Published:
Wednesday's top analyst upgrades and downgrades included Bluebird Bio, Boeing, Coinbase Global, Costco Wholesale, Envista, Merck, New Fortress Energy, NexTier Oilfield Solutions, Radius Global...
Published:
These are five biotech and medtech stocks for very aggressive accounts that look to get shares count leverage on companies that have sizable upside potential.
Published:
CymaBay Therapeutics posted a huge gain to start off the week after the company reported results from a late-stage clinical study for the treatment of primary biliary cholangitis.
Published:
CymaBay Therapeutics shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.
Published: